ANZCTR search results

Brief description of the study purpose The PRELuDE study aims to test whether personalised radionuclide treatment planning using a low dose tracer scan can accurately predict tumour radiation dose and improve how ¹77Lu PSMA radioligand therapy is prescribed for people with metastatic castration resistant prostate cancer. Who is it for? You may be eligible for this study if you are aged 18 years or older with metastatic castration resistant prostate cancer who have progressive disease despite standard treatments, have PSMA positive metastatic disease on imaging, adequate organ function, and are eligible to receive 177Lu PSMA therapy. Study details All participants will receive standard 177Lu PSMA therapy at a dose of 7400–8500 MBq for two treatment cycles. Participants will receive a tracer dose of 1000 MBq 177Lu PSMA before treatment. They will then undergo serial whole body planar imaging and SPECT CT scans at approximately 4 hours, 1 day, and 3–5 days after tracer injection to measure how much radiation is delivered to tumours and normal organs. These measurements will be used to calculate the predicted biologically effective dose (BED). The BED predicted from the tracer study will be compared with the BED measured after therapeutic administration using repeat imaging at the same time points. It is hoped that this research will validate a method for prospectively predicting tumour radiation dose, enabling more precise, efficient, and personalised radioligand therapy and improving treatment outcomes for people with advanced prostate cancer.

To examine the effect of a dedicated proactive multidisciplinary team review on blood glucose control and associated complications from compared with usual care. It is hypothesised that this intervention will result in reduced incidence of hospital acquired infection and improved blood sugar control.

Many adult distance runners sustain an injury caused by running each year, and there is limited high-quality evidence about how to prevent these injuries. This study aims to find out whether a gym-based exercise programme reduces the number of runners who become injured, compared with a home-based stretching programme. Adults aged 18 to 60 years who run at least twice per week and average at least 10 km per week will be randomly allocated to one of the two programmes, which they complete twice per week for six months alongside their usual running. Injuries and training will be monitored weekly using an online questionnaire, and lower-limb strength and jump performance will be measured at the start and end of the study. We expect that runners who complete the gym-based programme will be less likely to sustain a running-related injury over six months than those who complete the stretching programme.

Post-operative nausea and vomiting are common and distressing after bariatric (weight-loss) surgery, and can slow recovery and prolong hospital stay. This study tests whether a single oral dose of an anti-nausea medication (netupitant with palonosetron, marketed as Akynzeo), given about one hour before anaesthesia, reduces post-operative nausea and vomiting compared with standard anti-nausea care alone. Adults undergoing elective laparoscopic bariatric surgery are randomly allocated to receive either the study medication in addition to usual care or usual care alone, in an open-label design. We measure how often and how severely patients experience nausea and vomiting in the first week after surgery, together with pain, analgesic use, the need for rescue anti-nausea medication and length of hospital stay. We expect that adding this medication will reduce post-operative nausea and vomiting and improve early recovery, which could inform routine anaesthetic care for bariatric surgery.

Biliary atresia is a progressive, destructive process which becomes obvious over the first 3-6 months of a baby's life as they develop a specific type of jaundice and their stools become pale. Diagnosis of this in the premature and low birth weight population is difficult because the tests (ultrasound, nuclear medicine scans) are not very accurate at detecting structural changes. Our study aims to see if an alternative test, where a safe dye is injected intravenously, passes through the bloodstream and into the liver before entering the stools of babies can more accurately detect problems with the bile system. If the dye is found in the stools (dirty nappies) using a specialised camera, it shows the bile system is operating and if it is not detected, then the bile clearing system is potentially affected and the baby requires additional specialised invasive testing. If problems with the bile system can be accurately detected quickly, babies are more likely to have good response to surgery and avoided liver transplantation.

Around 12 participants will follow a fixed treatment plan to study how GV-100 interacts with other medicines. After screening, they will stay at the study site for about 2 weeks and return for a follow-up visit. They will first receive two medicines to check how their body processes them, then take GV-100 daily for 7 days. Later, the same medicines will be given again along with GV-100 to see if it changes how other drugs are handled in the body.

We recently collaborated with seven Australian adults living with HPP, and a carer of an adult living with HPP, to co-design a DVA-delivered health tool aimed at meaningfully supporting self-management of HPP. The participatory project explored the perspectives of those with lived experience of HPP, following the first three steps of the four-step Design Council Double Diamond Framework (Discover, Define, Develop, Deliver). In the Discover and Define phases, three priorities were identified: providing connection with peers, coordinating care, and supporting self-management. The most important features addressing each priority were then determined using structured prioritisation (i.e. video calls with peers, community noticeboard, health diary/ monitoring, healthcare professional database, education sessions, artificial intelligence-supported question and answer function, and nutrition/mental health support). During the Develop phase, the prioritised features were prototyped and presented for feedback. To address the final Deliver step of the Double Diamond framework, we will test the feasibility and preliminary effectiveness of using the DVA-delivered self-management program in a 12-week trial of adults living with HPP.

The aim of this study is to assess the amount of new bone volume that can be achieved using an established surgical technique know as guided bone regeneration (GBR). The regenerated bone will be used for the purpose of replacing missing teeth with dental implants. The study will be performed at a private specialist periodontal practice. In addition to assessing the volume of newly created bone, potential side effects such as swelling, pain and gum infection around the dental implants will be assessed for a period of up to 10 years from the GBR procedure.

The purpose of this study is to test whether MRI scans using non-standard imaging techniques can identify areas of prostate cancer that have low oxygen levels. Tumours with regions of low-oxygen may be at greater risk of metastatic spread and hence this project aims to build imaging biomarkers that may identify patients that may require additional treatment strategies to manage this risk. Who is it for? Participants may be eligible if aged 18 years or older, have localised intermediate- or high-risk prostate cancer, and have not yet started treatment. Study details Participants will be recruited and participate in this study before receiving their planned (standard of care) prostate cancer treatment. Before treatment starts, participants will undergo two additional MRI scans for research purposes, including one scan with a standard MRI contrast injection. For some participants, leftover tissue from their routine diagnostic biopsy will also be analysed. The researchers will compare the MRI results with the tissue findings to determine whether MRI can accurately identify low-oxygen areas within prostate cancer. The additional scans are not expected to delay initiation of standard-of-care treatment.

Left bundle area pacing is an emerging modality. The importance of continuous electrical monitoring during LBBAP pacemaker implantation has not been established. The CAPTURE trial analyses the principle that continouous electrical monitoring will improve acute implant physiological characteristics, and assesses the impact of implant electrical monitoring on clinical outcomes of pacemaker implantation.